We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Trellus Health Plc | TRLS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.15 | -6.52% | 2.15 | 11:00:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.30 | 1.90 | 2.30 | 2.15 | 2.30 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 17/1/2025 18:35 by dicko80 That’s a wrap on an incredible week at the 2025 J.P. Morgan Healthcare Conference!Trellus Health® was thrilled to connect with visionary healthcare leaders and investors who share our commitment to transforming chronic condition management. It was inspiring to showcase Trellus Elevate®, our resilience-driven digital solution, and discuss how we're improving outcomes, reducing costs, and enhancing quality of life. As we carry this momentum throughout 2025, we’re excited to continue building partnerships that make a real impact. Missed us at JPM? It’s not too late to explore how Trellus Elevate® can transform chronic condition management for your organization. Request a demo to learn more: hxxps://lnkd.in/ermV |
Posted at 15/1/2025 07:55 by pwhite73 The rise in the share price is caused by the momentum not the J & J news that probably adds no material financial value to the company.If the shares rise 100% retail investors pile in before it rises to 200%. When the shares rise to 200% retail investors pile in before it rises to 300% and so forth all the way up to yesterday's 725%. This happens more today over one stock than ever because losses and delistings are everywhere. There are so few AIM stocks now where opportunist retail investors can make a return. Trellus would already be forward selling discount placing shares to bolster its balance sheet. As the shares work their way through the markets they bring a halt to the momentum and everybody tries to pile out at the same time to protect their profits and avoid greater losses. The share price than collapses. Be careful. |
Posted at 14/1/2025 13:47 by darmz Yes but USA ?? investors can buy now they could have bought earlier morning. |
Posted at 14/1/2025 08:48 by soulac1 57% of shares are held by investors Significant shareholdersNo. of ordinary shares% heldIcahn School of Medicine at Mount Sinai40,384,89725.0% |
Posted at 14/1/2025 08:19 by soulac1 Not many shares here , big investors will start accumulating |
Posted at 03/10/2023 15:10 by hatfullofsky I was waiting for the user numbers too and to hear they have moved the 130 [paying] members $100 / month to a free service as part of a community feedback programme really hurt. There is clearly no demand in the D2C model and that's why they pushed the B2B emphasis on the investor call.If this tool does save money for the payer there is a clear business case. You could see the health care provider making it mandatory for all IBS / IBD sufferers. But the "potential share of savings" being the "significant upside" worries me when they have no users yet 6,200 members at $1,250 is breakeven £7.75m so current cash levels support the 2025 timeline. Their current pilot programmes have a TAM of 325 users and we'll only get results in Q2-24. They alluded to signing a major pilot programme (I guess before year end), that will attract interest and then the results in Q2 but really we are going to be waiting a long time for this to ignite |
Posted at 03/10/2023 08:37 by seadog40 Watched the investor call. Totally underwhelmed, but in absence of sensible user numbers/revenue there's not much else to say. The founder sounds very good and all the hard ground work seems to have been done. It's basically trading at the value of the cash held (about £11.5 my calc versus m'cap of £12.1)Does anyone have any thoughts on this as an investment. I'm actually in a small profit having bought loads at 5p. I like the people and believe in the product. I'd like to load up with more but, as yet, no one has proven that a demand exists for what it's offering. All opinions welcome. |
Posted at 25/4/2023 17:23 by idomeneo This might not be the bottom but I bought £5k here. There are lots of negatives, but there is time and cash (it qualifies as a Ben Graham Net Net which has returned 460% over the last 11 years). They may need a stock market oriented CEO who is prepared to do the things which creates the noise to get people interested, but in the meantime we have a results day plus hopefully an "Investor Meet Company" or similar following that. There was no liquidity for that £5k, so it is just available to private punters at this price. No guarantee at all of a long term win, but that doesn't have to matter. Could tank to 4p if they come with nothing to say. |
Posted at 19/1/2023 08:53 by wan The market is still unimpressed with Trellus, despite some positive news flow and change etc, but the market obviously wants more than a just a positive backdrop in terms of prospects.To repeat: Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS. I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. But the dynamics appear to be on the cusp of change with regard to pharma developments related to IBD. From the Trellus Health Half-year Report - "We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform." Pharmaceutical competition looks set to increase, which may increase the attention, and intensify the ongoing discussions with Trellus - January 17, 2023 Digesting 2022 and looking forward to 2023 in IBD therapeutics The past year has seen quite a few new developments in inflammatory bowel disease therapy. Other important developments to anticipate in 2023 include the introduction of as many as eight adalimumab biosimilars to the U.S. market, which almost certainly will drive the price of adalimumab down, and the potential approvals of subcutaneous Entyvio (vedolizumab, Takeda) and Inflectra (infliximab-dyyb, Celltrion) for the treatment of IBD. These therapeutics have already been approved in multiple other regions including Europe. It will be interesting to see what effect the availability of the adalimumab biosimilars and subcutaneous vedolizumab and infliximab-dyyb will have on treatment algorithms, especially if the cost differences are significant. I suspect it will take time for us to “digest” all these new developments, and the publication of real-world experiences with these new agents will help shape our clinical practice. Here’s looking to 2023! Full article - Food for thought: Dr. Dubinsky is co-founder and equity owner in a MiTest Health, which received a licensing fee from Takeda for CDPATH. Dr. Dubinsky has received compensation from both Takeda Pharmaceutical and Prometheus Laboratories as a consultant. In addition to Takeda, Dr. Dubinsky also serves as a paid consultant for other pharmaceutical companies that develop and/or manufacture treatments for inflammatory bowel disease (IBD). Dr. Dubinsky is co-founder and equity owner of two start-up companies involved in IBD healthcare, Trellus Health and GoDoRun. |
Posted at 06/12/2022 09:43 by wan Quiet here with the shares trading, by my estimate (cash at year-end in Dec equating to c10p per share), at a relatively small premium to expected cash levels and which provide a cash runway into 2025 which is based on managements conservative assumptions only.I note that Trellus has updated/revamped their website - Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS. I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. A reminder - "We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
